We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Precision Makes dPCR a Steadily Growing Sector

By LabMedica International staff writers
Posted on 06 Apr 2015
Print article
Kalorama Information (New York, NY, USA) has estimated that the budding market for digital PCR (dPCR) reached USD 175 million in 2014 and anticipated growth to provide products for research and diagnostics in diseases like cancer and neurological disorders.

Findings from Kalorama’s dPCR market analysis are provided in its report “qPCR and dPCR Markets,” covering instruments, reagents, software, and services. The report breaks out the market for clinical (in vitro diagnostics) and research applications sectors.

dPCR uses molecular counting to deliver an absolute measure of target nucleic acid molecules, rather than the relative measure obtained from qPCR. It works by partitioning the sample, into chambers (cdPCR) or droplets (ddPCR), to retain only a small number of DNA molecules of interest.

“dPCR is growing in popularity in labs because it is precise,” said Bruce Carlson, publisher of Kalorama Information, “It directly counts the number of individual target molecules in a sample and does not use approximation through standard curves.” Targets are counted as 1, non-targets are counted as 0. Because of its precision, dPCR is capable of analyzing complex mixtures and of performing procedures where only small sample amounts are available.

Kalorama’s report said that among developed nations, the US and Europe represent approximately 70% the dPCR market, which is anticipated to grow at a steady pace, whereas the qPCR segment is mature. “Companies will be looking to provide products to increase research and diagnostics in diseases like cancer, Alzheimer’s disease, and Parkinson’s disease,” said Mr. Carlson.

The competitive landscape for qPCR and dPCR markets is diverse, including large life sciences companies, large pharmaceutical company divisions, and many smaller niche players. According to the report, leading players in this arena are currently Life Technologies (Thermo Fisher Scientific), Bio-Rad, Qiagen, Roche and Agilent, Fluidigm and RainDance Technologies.

Related Links:

Kalorama Information
qPCR and dPCR Markets (Instruments, Reagents, Software/Services, Clinical and Research Markets), report


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Automated Blood Typing System
IH-500 NEXT
New
Vibrio Cholerae O1/O139 Rapid Test
StrongStep Vibrio Cholerae O1/O139 Antigen Combo Rapid Test
New
Silver Member
Apolipoprotein A-I Assay
Apo A-I Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.